Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases

Next Previous
Trial Profile

A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX-0158 (Primary)
  • Indications Cancer; Inflammation
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Nov 2015 According to a Kolltan Pharmaceuticals media release, the company plans to file an investigational new drug application (IND) for KTN0158 with the FDA in the Q4 of 2015, followed by the initiation of cancer clinical trials in 2016. The company also expects a second IND filing for KTN0158 for neurofibromatosis 1 (NF1) in 2016.
    • 05 Aug 2015 According to a Kolltan Pharmaceuticals media release, this trial is expected to begin in early 2016.
    • 08 Jul 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top